X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
FMXIN002 (epinephrine) is an adrenergic receptor agonist small molecule drug candidate, which is currently being evaluated for the treatment of anaphylaxis via intranasal spray.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: FMXIN002
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
Taffix powder creates a unique thin acidified gel above the nasal mucosa that lasts 5 hours, significantly shielding the nasal cells from inhaled viruses through both mechanical and chemical protection.
Lead Product(s): Hypromellose
Therapeutic Area: Infections and Infectious Diseases Product Name: TaffiX
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2021
Details:
Taffix® powder creates a unique thin acidified gel above the nasal mucosa that lasts 5 hours, significantly shielding the nasal cells from inhaled viruses through both mechanical and chemical protection.
Lead Product(s): Hypromellose
Therapeutic Area: Infections and Infectious Diseases Product Name: Taffix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2021
Details:
Data from a prospective clinical post marketing users survey shows that TaffixTM effectively blocks viruses from reaching nasal mucosa and was able to reduce infection rate of SARS-CoV-2 virus after super spread event by at least 4 fold.
Lead Product(s): Hypromellose
Therapeutic Area: Infections and Infectious Diseases Product Name: TaffiX
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
Gel layer produced by TaffiX® powder after administration of a clinical equivalent amount, effectively blocked SARS-CoV-2 virus, as demonstrated by four log reduction in amount of viral RNA and reduced the amount of infectious live virus by more than 99%.
Lead Product(s): Hypromellose
Therapeutic Area: Infections and Infectious Diseases Product Name: TaffiX
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
